Lysophosphatidylcholines are associated with P-tau181 levels in early stages of Alzheimer’s Disease
Preprint
Abstract
Background: We investigated systemic biochemical changes in Alzheimer’s disease (AD) by investigating the relationship between circulating plasma metabolites and both clinical and biomarker-assisted diagnosis of AD. Methods: We used an untargeted approach with liquid chromatography coupled to high-resolution mass spectrometry to measure exogenous and endogenous small molecule metabolites in plasma from 150 individuals clinically diagnosed with AD and 567 age-matched elderly without dementia of Caribbean Hispanic ancestry. Plasma biomarkers of AD were also measured including P-tau181, Aβ40, Aβ42, total tau, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP). Association of individual and co-expressed modules of metabolites were tested with the clinical diagnosis of AD, as well as biologically-defined AD pathological process based on P-tau181 and other biomarker levels. Results: Over 4000 metabolomic features were measured with high accuracy. First principal component (PC) of lysophosphatidylcholines (lysoPC) that bind to or interact with docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and arachidonic acid (AHA) was associated with decreased risk of AD (OR=0.91 [0.89-0.96], p=2e-04). Restricted to individuals without an APOE ε 4 allele (OR=0.89 [0.84-0.94], p= 8.7e-05), the association remained. Among individuals carrying at least one APOE ε 4 allele, PC4 of lysoPCs moderately increased risk of AD (OR=1.37 [1.16-1.6], p=1e-04). Essential amino acids including tyrosine metabolism pathways were enriched among metabolites associated with P-tau181 levels and heparan and keratan sulfate degradation pathways were associated with Aβ42/Aβ40 ratio reflecting different pathways enriched in early and middle stages of disease. Conclusions: Our findings indicate that unbiased metabolic profiling can identify critical metabolites and pathways associated with β-amyloid and phosphotau pathology. We also observed an APOE ε 4 dependent association of lysoPCs with AD and that biologically-based diagnostic criteria may aid in the identification of unique pathogenic mechanisms. GraphicalKeywords
This publication has 86 references indexed in Scilit:
- Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using MetabolomicsPLOS ONE, 2013
- Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's diseaseProgress in Neurobiology, 2012
- The sva package for removing batch effects and other unwanted variation in high-throughput experimentsBioinformatics, 2012
- Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer DiseaseJournal of Biological Chemistry, 2012
- Hydrophilic interaction liquid chromatography (HILIC)—a powerful separation techniqueAnalytical and Bioanalytical Chemistry, 2011
- Phospholipase A2 and arachidonic acid in Alzheimer's diseaseBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- MetaboAnalyst: a web server for metabolomic data analysis and interpretationNucleic Acids Research, 2009
- apLCMS—adaptive processing of high-resolution LC/MS dataBioinformatics, 2009
- WGCNA: an R package for weighted correlation network analysisBMC Bioinformatics, 2008
- Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's diseaseNature Neuroscience, 2008